二甲基氧化膦 | 7211-39-4

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦及其衍生物
• 中文名称: 二甲基氧化膦
• 中文别名: 二甲基膦氧化物
• 英文名称: dimethyl phosphine oxide
• 英文别名: methylphosphonoylmethane；dimethylphosphorus oxide；dimethylphosphinoxide；dimethyl-λ⁵-phosphanone；dimethyl-lambda⁵-phosphanone；dimethylphosphine hydrogen
• CAS: 7211-39-4
• 化学式: C₂H₇OP
• 分子量: 78.0507
• InChiKey: HGDIHUZVQPKSMO-UHFFFAOYSA-N

物化性质

• 沸点：
  65-67 °C(Press: 6 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P210,P233,P240,P241,P242,P243,P261,P264,P270,P271,P273,P280,P301+P312,P321,P330,P332+P313,P337+P313,P362+P364,P370+P378,P403+P233,P403+P233,P403+P233,P403+P235,P405,P501
• 危险品运输编号：
  1993
• 危险性描述：
  H225,H302+H312+H332,H315,H319,H335,H412
• 储存条件：
  室温且干燥

SDS

---

Section 1: Product Identification
Chemical Name: Dimethylphosphine oxide, min. 97%
CAS Registry Number: 7211-39-4
Formula: (CH3)2P(O)H
EINECS Number: none
Chemical Family: organophosphorus compound
Synonym: Dimethylphosphorus oxide

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title compound 7211-39-4 100% no data no data

---

Section 3: Hazards Identification
Emergency Overview: Irritating to skin, eyes and respiratory tract. May be harmful if swallowed.
Primary Routes of Exposure: Inhalation, skin, eyes.
Eye Contact: Causes moderate irritation of the eyes.
Skin Contact: Causes irritation of the skin. May cause redness, itching and pain.
Inhalation: Irritating to the nose, mucous membranes and respiratory tract.
Ingestion: No specific information is available on the physiological effects of ingestion. May be harmful if swallowed.
Acute Health Affects: Irritating to skin, eyes and respiratory tract.
Chronic Health Affects: No information on long-term chronic effects.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: no data
Autoignition Temperature: no data
Explosion Limits: no data
Extinguishing Medium: carbon dioxide, dry powder or foam.
Fire fighters should be equipped with a NIOSH approved positive pressure self-contained breathing apparatus
Special Fire Fighting Procedures:
and full protective clothing.
Hazardous Combustion and If involved in a fire this material may emit toxic organic fumes.
Decomposion Products:
Unusual Fire or Explosion Hazards: Contact of dimethylphosphine oxide with carbon tetrachloride leads to explosive decomposition.

---

SECTION 6: Accidental Release Measures
Small spills can be mixed with vermiculite, sodium carbonate or other suitable non combustible adsorbent and
Spill and Leak Procedures:
swept up.

---

SECTION 7: Handling and Storage
Handling and Storage: Keep container tightly closed. Store in a cool, dry place.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves.
Ventilation: Handle the material in an efficient fume hood.
If ventilation is not available a respirator should be worn. The use of respirators requires a Respirator
Respirator:
Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: Handle the material in an efficient fume hood.
Additional Protection: No additional protection required.

---

SECTION 9: Physical and Chemical Properties
Color and Form: white solid
Molecular Weight: 78.05
Melting Point: no data
Boiling Point: no data
Vapor Pressure: no data
Specific Gravity: no data
Odor: musty odor
Solubility in Water: slightly soluble

---

SECTION 10: Stability and Reactivity
Stability: air and moisture stable
Hazardous Polymerization: no hazardous polymerization
Conditions to Avoid: contact with carbon tetrachloride leads to explosive decomposition.
Incompatibility: oxidizing agents, active metals, carbon tetrachloride and halogens.
Decomposition Products: carbon dioxide, carbon monoxide, organic fumes and phosphorus oxides.

---

SECTION 11: Toxicological Information
RTECS Data: No information available in the RTECS files.
Carcinogenic Effects: no data
Mutagenic Effects: no data
Tetratogenic Effects: no data

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to federal, state, and local regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Non-hazardous
Hazard Class (CFR): NA
Additional Hazard Class (CFR): NA
Packaging Group (CFR): NA
UN ID Number (CFR): NA
Shipping Name (IATA): Non-hazardous
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): NA

---

SECTION 15: Regulatory Information
TSCA: Not listed in the TSCA inventory.
SARA (Title 313): Title compound not listed.
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

二甲基氧化膦简介

二甲基氧化膦是一种有机磷化合物。它是一种无色液体，可溶于极性有机溶剂，并以氧化膦的形式存在而非羟基互变异构体。相关化合物是二苯基膦氧化物，两者有时都被称为仲膦氧化物。

制备方法

该化合物可通过氯二甲基膦与水反应制得： [ \text{Me}_2\text{PCl} + \text{H}_2\text{O} \rightarrow \text{Me}_2\text{P(O)H} + \text{HCl} ]

此外，也可以使用甲醇代替水进行此反应，副产物为氯甲烷。

用途

二甲基氧化膦用作有机合成中的中间体。

反应信息

• 作为反应物：
  描述：

  二甲基氧化膦 在 五氯化磷 作用下， 生成 氯甲基(二甲基)氧膦
  参考文献：
  名称：

  Tsvetkov, E. N.; Tkachenko, S. E.; Yarkevich, A. N., Bulletin de la Societe Chimique de France, 1988, # 2, p. 339 - 341

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基氯化镁 在 亚磷酸二乙酯 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以70.8%的产率得到二甲基氧化膦
  参考文献：
  名称：

  [EN] ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER
  [FR] DISPOSITIF ÉLECTRONIQUE ORGANIQUE COMPRENANT UNE COUCHE SEMI-CONDUCTRICE ORGANIQUE

  摘要：

  本发明涉及一种化合物的化学式1和包括有机半导体层的有机电子器件，其中至少一个有机半导体层包括一个化合物的化学式（1），其中L1具有化学式（2），L2具有化学式（3），其中L1和L2通过单键独立地与Ar1的相同或不同的芳基或杂芳基通过“*”键合；其中X1、X2独立选择自O、S和Se；Ar1选择自取代或未取代的C20至C52芳基或C14至C64杂芳基，其中取代的C20至C52芳基或C14至C64杂芳基的取代基独立选择自C1至C12烷基、C1至C12烷氧基、CN、卤素、OH、C6至C25芳基和C2至C21杂芳基；R1、R2独立选择自取代或未取代的C1至C16烷基，其中取代的C1至C16烷基的取代基选择自C6至C18芳基或C2至C12杂芳基；R3、R4独立选择自取代或未取代的C1至C16烷基，取代或未取代的C6至C18芳基，C2至C20杂芳基，其中取代的C1至C16烷基、取代的C6至C18芳基、C2至C20杂芳基的取代基独立选择自C6至C18芳基或C2至C12杂芳基；n选择自1至5，其中n为整数。

  公开号：

  WO2018215348A1
• 作为试剂：
  描述：

  2-碘苯胺 在 palladium diacetate 、 二甲基氧化膦 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以60.42%的产率得到(2-氨基苯基)二甲基氧化膦
  参考文献：
  名称：

  [EN] TYK2 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。

  公开号：

  WO2018075937A1

文献信息

• [EN] COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS<br/>[FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR
  申请人：ARIAD PHARMA INC

  公开号：WO2013169401A1

  公开（公告）日：2013-11-14

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

  这项发明涉及化合物、药物组合物和治疗EGFR驱动的Formula (I)癌症患者的方法，其中变量如本文所定义。
• 一种β-氰基膦酰类衍生物及其制备方法与应 用
  申请人：苏州大学

  公开号：CN106432329B

  公开（公告）日：2018-07-31

  本发明公开了一种β‑氰基膦酰类衍生物及其制备方法与应用。本发明使用烯烃为起始物，原料易得，种类广泛；利用本发明方法得到的产物类型多样，用途广泛，既可直接使用，又可用于合成有机膦阻燃剂、药物和萃取剂；此外，本发明公开的方法步骤简单、反应条件温和、目标产物的收率高、污染小、反应操作和后处理过程简单，适合于工业化生产。
• [EN] SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1 TRICYCLIQUES SPIRO FUSIONNÉS
  申请人：BAYER AG

  公开号：WO2021074279A1

  公开（公告）日：2021-04-22

  The present invention relates to Map4K1 inhibitors of formula (I) to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的MAP4K1抑制剂，以及包含根据本发明的化合物的药物组合物和组合物，以及创新化合物的预防性和治疗性用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病，癌症或与异常MAP4K1信号相关的其他紊乱免疫反应或其他紊乱的疾病，作为单一药剂或与其他活性成分组合使用。本发明还涉及使用，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物的用途。
• [EN] PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE<br/>[FR] COMPOSÉS INHIBITEURS DE PHD, COMPOSITIONS ET UTILISATION
  申请人：AKEBIA THERAPEUTICS INC

  公开号：WO2021188938A1

  公开（公告）日：2021-09-23

  The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart ( e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.

  本发明部分提供了PHD的新型小分子抑制剂，其结构符合式（A）及其亚式结构：或其药学上可接受的盐。本文提供的化合物可用于治疗包括心脏病（例如缺血性心脏病、充血性心力衰竭和瓣膜性心脏病）、肺部疾病（例如急性肺损伤、肺动脉高压、肺纤维化和慢性阻塞性肺疾病）、肝脏疾病（例如急性肝功能衰竭和肝纤维化和肝硬化）和肾脏疾病（例如急性肾损伤和慢性肾脏疾病）的疾病。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。